TrialThe oncologist2018

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).

Goro Nakayama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.